NuggMD releases landmark 210k-record patient study on medical cannabis trends


Ryan Allway

January 5th, 2023

News, Top News


New York, NY | January 05, 2023 – As legal cannabis continues to enjoy broad, bipartisan support among the general public and as more states legalize the substance for either medical or recreational purposes, a recently released landmark study sheds new light on the conditions for which patients seek medical cannabis and how those conditions vary by geographic region, age, and gender identity.

 

The study, the 2022 Cannabis Conditions Report, was conducted by NuggMD using more than 210,000 anonymized patient records, among the largest data sets of its kind. NuggMD is a telemedicine provider that helps patients obtain medical cannabis cards in 22 states. It conducted the study in order to add more facts to the prevailing dialogue about the addition of medical cannabis to a treatment regimen.

 

The full report is available here. It was first reported by Marijuana Moment, one of the nation’s leading trackers of developments and news in the cannabis industry.

 

Concurrent with its Conditions Report, NuggMD also released the details of a complementary survey of more than 500 current medical cannabis card-holders. Importantly, 68 percent of respondents said they have ceased or reduced other pharmaceutical treatments since incorporating medical cannabis. More than 80 percent of respondents said they are comfortable discussing medical cannabis with their doctors, and more than 94 percent said cannabis provides to them moderate or total relief of the conditions for which they sought treatment.

 

“The evidence here is clear: medical cannabis works. It provides relief for a wide variety of conditions. More importantly, it’s giving patients an alternative to dangerously addictive, often deadly pharmaceuticals. More than a century of disinformation and propaganda peddled by cannabis foes does not change these facts,” said Alex Milligan, co-founder and chief marketing officer of NuggMD.

 

Analysis: Inconsistent standards limit access and create unreliable data

Still, a significant barrier to access is how states limit the qualifying conditions for which a patient may be recommended medical cannabis. In some states, legislators have expanded their regulations to include more qualifying conditions or to allow physicians to recommend medical cannabis in broad terms, such as for treatment of a “debilitating medical condition.” Other states continue to unjustly prohibit their residents from accessing this form of healthcare.

 

Of note, the states that allow physicians to determine the qualifying condition saw a higher rate of patients reporting “other condition” as a reason they were seeking medical cannabis. Based on that datapoint, NuggMD believes that states with fewer qualifying conditions are either deterring patients from seeking the medication they need or reducing the accuracy of available data by forcing patients in need of medical cannabis to select a comorbidity rather than the primary ailment for which they were seeking an evaluation. A majority of patients in the study listed multiple conditions, which can be expected as many conditions exist co-morbidly.

 

“From a policy standpoint, one piece of low-hanging fruit for lawmakers is more consistency to the qualifying conditions under which states approve medical cannabis licenses for patients,” said Milligan. “The current status quo does not promote equal access to care or the evidence-based evaluation of medical outcomes, which are both cornerstones of other areas of healthcare.”

 

The report was authored by NuggMD’s Alexandra Arnett, a University of Maryland School of Pharmacy candidate for a Master of Science in Medical Cannabis Science and Therapeutics. Medical review was provided by Dr. Brian Kessler, MD, Pain Management & Sports Medicine, with analysis, editing, and fact-checking conducted by NuggMD’s Tyler Elson and Deb Tharp.

 

About NuggMD

 

NuggMD is the nation’s leading medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They’ve connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com.

 

Contact Details

Andrew Graham

andrew.g@getnugg.com

 

Company Website

http://www.nuggmd.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading